Update on the role of endovesical chemotherapy in nonmuscle-invasive bladder cancer
Actas Urol Esp (Engl Ed). 2018 Mar;42(2):73-76.
doi: 10.1016/j.acuro.2017.09.006.
Epub 2017 Nov 10.
[Article in
English,
Spanish]
Affiliations
- 1 Hospital Universitario Basurto, Bilbao, España. Electronic address: jesusmiguel.undaurzaiz@osakidetza.eus.
- 2 Complejo Universitario de Asturias, Oviedo, Asturias, España.
- 3 Hospital Universitario Virgen de las Nieves, Granada, España.
- 4 Hospital de Jerez, Jerez de la Frontera, Cádiz, España.
- 5 Fundación Puigvert, Barcelona, España.
- 6 Hospital Universitario La Paz, Madrid, España.
No abstract available
MeSH terms
-
Administration, Intravesical
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Transitional Cell / drug therapy*
-
Carcinoma, Transitional Cell / epidemiology
-
Carcinoma, Transitional Cell / pathology
-
Carcinoma, Transitional Cell / surgery
-
Combined Modality Therapy
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Epirubicin / administration & dosage
-
Epirubicin / adverse effects
-
Humans
-
Mitomycin / administration & dosage
-
Mitomycin / adverse effects
-
Neoplasm Invasiveness
-
Neoplasm Recurrence, Local / prevention & control
-
Practice Guidelines as Topic
-
Urinary Bladder Neoplasms / drug therapy*
-
Urinary Bladder Neoplasms / epidemiology
-
Urinary Bladder Neoplasms / pathology
-
Urinary Bladder Neoplasms / surgery
Substances
-
Epirubicin
-
Mitomycin
-
Doxorubicin